Egypt Immuno-Oncology Research Review Issue 6

In this issue:
  -  Sintilimab + chemotherapy for locally advanced/metastatic oesophageal SCC
  -  Pembrolizumab in completely resected stage IIB or IIC melanoma
  -  Nivolumab + chemotherapy in resectable lung cancer
  -  Adjuvant durvalumab uptake after chemoradiotherapy for stage III NSCLC
  -  Nivolumab + ipilimumab for unresectable malignant pleural mesothelioma
  -  Maintenance ICIs ±pemetrexed in advanced nonsquamous NSCLC
  -  Nivolumab + ipilimumab vs. sunitinib in advanced RCC
  -  Lenvatinib ±ICI for unresectable HCC in the real world
  -  Pembrolizumab for advanced HCC previously treated with sorafenib
  -  Pembrolizumab in MSI-high advanced endometrial cancer
  -  Pembrolizumab for MSI-high/ mismatch repair-deficient metastatic CRC

Download PDF Subscribe